Prothrombotic factors, including factor V leiden mutations (19%), antiphospholipid antibodies (16%), and protein C deficiency (15%) were identified in those JAK2 V617F positive patients, but prevalence of OCP use was unknown [22]. The gene discussed is F5; the disease is hyperinsulinemic hypoglycemia, familial, 4.